March 2023

Smoking increases the risk of developing severe COVID by 30 to 50%

Leave a Comment / Cancer, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Tobacco control research  / By

This is the main conclusion of a study published in the scientific journal ‘European Respiratory Review’ in which the head of the IDIBELL Tobacco Control research group and head of the Tobacco Control Unit of the Catalan Institute of Oncology, Esteve Fernández, has participated. The article analyzes the results in this field in the different reports presented to date.

Smoking increases the risk of developing severe COVID by 30 to 50% Read More »

The Association Against Cancer in Barcelona finances four IDIBELL projects with almost 500,000 euros

Leave a Comment / Sin categorizar / By

The IDIBELL projects by Elisa Espinet, Juan José Rojas, Carolina M. Florian, and Victor Moreno have been selected. All of them presented this Monday in an act with a round table of the most outstanding grants and a dialogue between doctor and patient.

The Association Against Cancer in Barcelona finances four IDIBELL projects with almost 500,000 euros Read More »

New study identifies an epigenetic signature associated to the rare genetic disorder GATA2 deficiency

Leave a Comment / Hematopoietic Stem Cell Biology And Leukemogenesis, Regenerative Medicine Area, Regenerative Medicine Program / By

The results show that patients with this disorder have abnormal genetic and epigenetic patterns, which could contribute to the development of diverse clinical manifestations, such as compromise the ability of blood cell production.

New study identifies an epigenetic signature associated to the rare genetic disorder GATA2 deficiency Read More »

IDIBELL and CNIO researchers propose biomarkers to select patients with breast cancer who could benefit from treatment with Denosumab

Leave a Comment / Sin categorizar / By

“These results reactivate the option of clinical trials with Denosumab in breast cancer selected patients”, says Eva González-Suarez, CNIO and IDIBELL researcher and lead author.

IDIBELL and CNIO researchers propose biomarkers to select patients with breast cancer who could benefit from treatment with Denosumab Read More »

Brachytherapy in early-stage breast cancer tumors is faster and with fewer side effects than conventional radiotherapy

Leave a Comment / Cancer, Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell, Radiobiology & Cancer / By

These are the results of an international study with the participation of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Valencian Institute of Oncology (IVO) and in which they make a comparison between the two techniques.

Brachytherapy in early-stage breast cancer tumors is faster and with fewer side effects than conventional radiotherapy Read More »

Bellvitge Hospital, IDIBELL and Astrazeneca test an application that monitors heart failure using voice

Leave a Comment / Cardiovascular Diseases Research Group (BIO-HEART), Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Translational Medicine Area / By

Through a mobile device, HearO™ makes it possible to predict possible complications in patients with heart failure through speech, detect disease-related fluid accumulation and alert the doctor before hospitalization

Bellvitge Hospital, IDIBELL and Astrazeneca test an application that monitors heart failure using voice Read More »

Research team from IDIBELL and UB find that HERC1 protein deficiency causes osteopenia

Leave a Comment / Cell signalling and bone biology, Diabetes and Metabolism Program, Translational Medicine Area / By

Scientists from IDIBELL and the University of Barcelona identify how HERC1 deficiency unbalances bone homeostasis, causing osteopenia. These results identify potential therapeutic targets for individuals with bone diseases and HERC1 deficiency.

Research team from IDIBELL and UB find that HERC1 protein deficiency causes osteopenia Read More »

New evidence for the correct detection of oropharyngeal cancers caused by the human papillomavirus

Leave a Comment / Cancer, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Infections and Cancer / By

To establish whether oropharyngeal cancer was related to the human papillomavirus, the recomendation is do it through the p16 protein detection.
Now a study from IDIBELL published in The Lancet Oncology has shown that not all p16-positive oropharyngeal cancers are caused by the virus.

New evidence for the correct detection of oropharyngeal cancers caused by the human papillomavirus Read More »

An investigation by HUB and IDIBELL shows the adaptation of bacteria in COPD patients and prolonged treatment with azithromycin

Epidemiology of  bacterial infections, pathogenesis and molecular basis of antimicrobial resistance , Infectious disease and transplantation Program, Translational Medicine Area / By

The IDIBELL Bacterial Epidemiology research group has published a paper on the adaptation of Haemophilus spp in patients with chronic obstructive pulmonary disease (COPD) and prolonged treatment with azithromycin.

An investigation by HUB and IDIBELL shows the adaptation of bacteria in COPD patients and prolonged treatment with azithromycin Read More »

Scroll to Top